Literature DB >> 11544363

Bacteriophage therapy.

W C Summers1.   

Abstract

In 1917, bacteriophages were recognized as epizootic infections of bacteria and were almost immediately deployed for antibacterial therapy and prophylaxis. The early trials of bacteriophage therapy for infectious diseases were confounded, however, because the biological nature of bacteriophage was poorly understood. The early literature reviewed here indicates that there are good reasons to believe that phage therapy can be effective in some circumstances. The advent of antibiotics, together with the "Soviet taint" acquired by phage therapy in the postwar period, resulted in the absence of rigorous evaluations of phage therapy until very recently. Recent laboratory and animal studies, exploiting current understandings of phage biology, suggest that phages may be useful as antibacterial agents in certain conditions.

Entities:  

Mesh:

Year:  2001        PMID: 11544363     DOI: 10.1146/annurev.micro.55.1.437

Source DB:  PubMed          Journal:  Annu Rev Microbiol        ISSN: 0066-4227            Impact factor:   15.500


  139 in total

1.  Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections.

Authors:  Caroline Westwater; Laura M Kasman; David A Schofield; Phillip A Werner; Joseph W Dolan; Michael G Schmidt; James S Norris
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

2.  The genome sequence of Yersinia pestis bacteriophage phiA1122 reveals an intimate history with the coliphage T3 and T7 genomes.

Authors:  Emilio Garcia; Jeffrey M Elliott; Erlan Ramanculov; Patrick S G Chain; May C Chu; Ian J Molineux
Journal:  J Bacteriol       Date:  2003-09       Impact factor: 3.490

3.  Impact of relative humidity and collection media on mycobacteriophage D29 aerosol.

Authors:  Keyang Liu; Zhanbo Wen; Na Li; Wenhui Yang; Jie Wang; Lingfei Hu; Xiaokai Dong; Jianchun Lu; Jinsong Li
Journal:  Appl Environ Microbiol       Date:  2011-12-22       Impact factor: 4.792

4.  Enumeration of bacteriophage particles: Comparative analysis of the traditional plaque assay and real-time QPCR- and nanosight-based assays.

Authors:  Bradley Anderson; Mohammed H Rashid; Chandi Carter; Gary Pasternack; Chythanya Rajanna; Tamara Revazishvili; Timothy Dean; Andre Senecal; Alexander Sulakvelidze
Journal:  Bacteriophage       Date:  2011-03

5.  Genetically engineered virulent phage banks in the detection and control of emergent pathogenic bacteria.

Authors:  Flavie Pouillot; Hélène Blois; François Iris
Journal:  Biosecur Bioterror       Date:  2010-06

6.  Efficacy and pharmacokinetics of bacteriophage therapy in treatment of subclinical Staphylococcus aureus mastitis in lactating dairy cattle.

Authors:  J J Gill; J C Pacan; M E Carson; K E Leslie; M W Griffiths; P M Sabour
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

7.  A synthetic phage lambda regulatory circuit.

Authors:  Shota Atsumi; John W Little
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-29       Impact factor: 11.205

8.  Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections.

Authors:  Marine Henry; Rob Lavigne; Laurent Debarbieux
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

9.  Making a Virus Visible: Francis O. Holmes and a biological assay for tobacco mosaic virus.

Authors:  Karen-Beth G Scholthof
Journal:  J Hist Biol       Date:  2014       Impact factor: 1.326

10.  Phage Therapy - Everything Old is New Again.

Authors:  Andrew M Kropinski
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-09       Impact factor: 2.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.